FLT3 inhibitors for the treatment of autoimmune disease

Expert Opin Investig Drugs. 2008 Nov;17(11):1685-92. doi: 10.1517/13543784.17.11.1685.

Abstract

Background: Autoimmune diseases encompass a broad range of illnesses with a variety of underlying causes, some of which are known and some of which remain elusive.

Objective: The focus of this review will be on describing the development of a new type of therapy that could potentially treat T cell-mediated autoimmune diseases. Unlike traditional therapies, which have primarily focused on suppressing T cells directly, targeting the step of antigen presentation may allow a less toxic therapy in which autoimmunity is lessened without compromising the entire immune system. This review will outline the science behind the development of the therapy, the roles of dendritic cells in generating autoimmune disease, and the function of the FLT3 receptor in this process.

Publication types

  • Review

MeSH terms

  • Animals
  • Autoimmune Diseases / drug therapy*
  • Autoimmune Diseases / enzymology*
  • Autoimmune Diseases / genetics
  • Autoimmune Diseases / immunology
  • Dendritic Cells / immunology
  • Drug Evaluation, Preclinical
  • Humans
  • Protein Kinase Inhibitors / therapeutic use*
  • Signal Transduction / drug effects
  • fms-Like Tyrosine Kinase 3 / antagonists & inhibitors*
  • fms-Like Tyrosine Kinase 3 / metabolism

Substances

  • Protein Kinase Inhibitors
  • fms-Like Tyrosine Kinase 3